PT - JOURNAL ARTICLE AU - Christopher B. Mahony AU - Boris Noyvert AU - Pavle Vrljicak AU - Sascha Ott AU - Martin Higgs AU - Rui Monteiro TI - Gata2a maintains <em>cebpa</em> and <em>npm1a</em> in haematopoietic stem cells to sustain lineage differentiation and genome stability AID - 10.1101/2021.07.19.452890 DP - 2021 Jan 01 TA - bioRxiv PG - 2021.07.19.452890 4099 - http://biorxiv.org/content/early/2021/07/19/2021.07.19.452890.short 4100 - http://biorxiv.org/content/early/2021/07/19/2021.07.19.452890.full AB - The transcription factor Gata2 is required to produce and maintain haematopoietic stem and progenitor cells (HSPCs) in development and adult haematopoiesis. Mutations in GATA2 lead to GATA2 deficiency syndrome and predispose patients to acquire leukaemia. Here we use zebrafish gata2a enhancer deletion mutants and single cell transcriptomics to understand how GATA2 mediates survival and differentiation of haematopoietic stem cells in GATA2 deficiency. Gata2a mutants show marrow failure, neutropenia, B-lymphopenia and erythrocytosis from 6 months post-fertilization (mpf). Single cell transcriptional profiling of the adult kidney marrow demonstrated that HSPCs express elevated expression of erythroid- and decreased expression of myeloid genes, including cebpa. This is associated with a lineage skewing towards the erythroid fate at the expense of the myeloid fate. Thus, Gata2a is required to initiate and maintain lineage priming in HSPCs, favouring myeloid differentiation. Gata2a regulates expression of multiple targets associated with replication and DNA damage repair (DDR), including npm1a, a zebrafish NPM1 orthologue. Accordingly, mutant marrow cells show increased DNA damage associated with progressive loss of npm1a expression with age. This effect was replicated by inhibiting NPM1 activity in murine HPC7 progenitor cells. We propose that the impaired DDR leads to marrow failure in GATA2 deficiency. This leads to increased genomic instability in the surviving HSPCs, favouring acquisition of secondary leukaemogenic mutations.Competing Interest StatementThe authors have declared no competing interest.